NCT04976803View on ClinicalTrials.gov

Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein

CompletedOBSERVATIONAL
Enrollment

229

Participants

Timeline

Start Date

May 28, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Solid Tumor, Unspecified, Adult
Interventions
OTHER

Determination of ATM alteration status.

ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.

Trial Locations (3)

37104

Oklahoma University, Oklahoma City

37203

Tennessee Oncology, Nashville

W1G6AD

Sarah Cannon Research UK, London

Sponsors

Lead Sponsor

Artios Pharma Ltd
All Listed Sponsors
lead

Artios Pharma Ltd

INDUSTRY

NCT04976803 - Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein | Biotech Hunter | Biotech Hunter